BC
AUPH icon

Bridgefront Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bridgefront Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,606
Closed -$149K – 618
2024
Q4 		$149K Buy
16,606
+1,891
+13% +$15.4K 0.05% 523
2024
Q3 		$108K Buy
+14,715
New +$91.2K 0.04% 491
2024
Q2 		– Sell
-10,279
Closed -$51.5K – 485
2024
Q1 		$51.5K Buy
+10,279
New +$69.7K 0.04% 355
2023
Q4 		– Sell
-12,812
Closed -$99.5K – 372
2023
Q3 		$99.5K Buy
+12,812
New +$125K 0.07% 360
2021
Q3 		– Sell
-11,040
Closed -$143K – 333
2021
Q2 		$143K Buy
+11,040
New +$141K 0.05% 536

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridgefront Capital's AUPH Position: Q1 2025 in Review

Bridgefront Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 16,606 shares — an estimated $149K sold.

Bridgefront Capital first reported a position in AUPH in Q2 2021 and held it in 5 quarters. The position peaked at $149K in Q4 2024. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • Bridgefront Capital reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Bridgefront Capital sold 16,606 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $149K.
  • Bridgefront Capital first reported a position in Aurinia Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Bridgefront Capital's Aurinia Pharmaceuticals position peaked at $149K in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Bridgefront Capital's 13F filing for Q1 2025, filed 15 May 2025.